Microglia actions in Alzheimer's disease
The DOI matches its Crossref record; 171 of the 175 references it cites were found in a registry or an index.
Abstract
The identification of microglia-associated, neurological disease-causing mutations in patients, combined with studies in mouse models has highlighted microglia, the brain’s intrinsic myeloid cells, as key modulators of pathogenesis and disease progression in neurodegenerative diseases. In Alzheimer’s disease (AD) in particular, the activation and accumulation of microglial cells around b-Amyloid (Ab) plaques has long been described and is believed to result in chronic neuroinflammation—a term that, despite being commonly used, lacks a precise definition. This seemingly directed response of microglia to amyloid deposits conflicts with the fact that the increasing buildup of Ab plaques is not inhibited by these cells during disease progression. While recent evidence suggests that microglia lose their intrinsic beneficial function during the course of AD and may even acquire a ‘‘toxic’’ phenotype over time, Ab may also simply not be an appropriate trigger to induce phagocytosis and degradation by microglia in vivo. As recent experimental evidence has indicated the importance of the microglia in AD pathogenesis, future efforts aimed at tackling this disease via utilization or modulation of microglia or factors therefrom appear to be an exciting and challenging research front.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“But in point of fact, is has been argued that there has yet to be sufficient evidence that microglia are capable of true phagocytosis of Aβ [149]”
From Microglial dysfunction in brain aging and Alzheimer's disease (2014) · cites this paper as [149]
In the citing paper
“although microglia do appear to engulf amyloid, it is unclear whether the cells can degrade the protein.”
From Microglial dysfunction in brain aging and Alzheimer's disease (2014) · cites this paper as [149]
Citations
Cites
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123 · cited 1×
“Stage-specific accumulation of Ab [101] and neurofibrillary tangles [14] are the pathological hallmarks of AD.”
BackgroundMacrophage plasticity and polarization: in vivo veritas
Sica, A., & Mantovani, A. (2012) · Journal of Clinical Investigation · doi:10.1172/jci59643 · Cited by 6,335 · cited 1×
“Recently, the concept of classifying peripheral macrophages according to the type of T-cell mediated stimulation in ‘‘M1’’ (‘‘classically activated’’) and ‘‘M2’’ (‘‘alternatively activated’’) activation states [127] has been transferred to microglia [11] in an attempt to illustrate context-dependent microglia activati…”
Fate Mapping Analysis Reveals That Adult Microglia Derive from Primitive Macrophages
Ginhoux, F., Greter, M., Leboeuf, M., Nandi, S., See, P., Gokhan, S., Mehler, M. F., Conway, S. J., Ng, L. G., Stanley, E. R., et al. (2010) · Science · doi:10.1126/science.1194637 · Cited by 5,175 · cited 1×
“As microglia constitute a population of cells ontologically distinct from rapidly renewed blood monocytes [48, 72, 122], their proper function is an undeniably critical factor for CNS homeostasis, especially in light of the limited renewability of the brain.”
BackgroundMirra, S. S., Heyman, A., McKeel, D., Sumi, S. M., Crain, B. J., Brownlee, L. M., Vogel, F. S., Hughes, J. P., Belle, G. V., Berg, L., et al. (1991) · Neurology · doi:10.1212/wnl.41.4.479 · Cited by 4,961
Querfurth, H. W., & LaFerla, F. M. (2010) · New England Journal of Medicine · doi:10.1056/nejmra0909142 · Cited by 4,569
Inflammation and Alzheimer’s disease
Akiyama, H. (2000) · Neurobiology of Aging · doi:10.1016/s0197-4580(00)00124-x · Cited by 4,514
Cellular senescence: when bad things happen to good cells
Campisi, J., & d'Adda di Fagagna, F. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2233 · Cited by 4,441 · cited 1×
“aging process in which mitotic cells exhibit growth arrest, apoptosis resistance and characteristic alterations in gene expression [19].”
BackgroundMicroglia: a sensor for pathological events in the CNS
Kreutzberg, G. W. (1996) · Trends in Neurosciences · doi:10.1016/0166-2236(96)10049-7 · Cited by 4,396 · cited 1×
“phagocytosis [78], and there have been numerous studies reporting microglial phagocytosis of Ab as a key mechanism of the brain’s defense against the accumulation of Ab [40, 42, 126, 157].”
BackgroundSynaptic Pruning by Microglia Is Necessary for Normal Brain Development
Paolicelli, R. C., Bolasco, G., Pagani, F., Maggi, L., Scianni, M., Panzanelli, P., Giustetto, M., Ferreira, T. A., Guiducci, E., Dumas, L., et al. (2011) · Science · doi:10.1126/science.1202529 · Cited by 4,244 · cited 1×
“Moreover, whether microglia and peripheral macrophages have functionally overlapping or distinct capabilities, especially in respect to the highly specialized roles attributed to microglia in the brain, including regulation of synaptic plasticity and neurogenesis, needs to be investigated [108, 128].”
BackgroundImmunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse
Schenk, D., Barbour, R., Dunn, W., Gordon, G., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., Khan, K., et al. (1999) · Nature · doi:10.1038/22124 · Cited by 3,160
TREM2 Variants in Alzheimer's Disease
Guerreiro, R., Wojtas, A., Bras, J., Carrasquillo, M., Rogaeva, E., Majounie, E., Cruchaga, C., Sassi, C., Kauwe, J. S. K., Younkin, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1211851 · Cited by 3,020 · cited 2×
“risk factors for AD [53, 70], microglia, the brain’s intrinsic macrophages, almost suddenly became very important cells.”
BackgroundNLRP3 is activated in Alzheimer’s disease and contributes to pathology in APP/PS1 mice
Heneka, M. T., Kummer, M. P., Stutz, A., Delekate, A., Schwartz, S., Vieira-Saecker, A., Griep, A., Axt, D., Remus, A., Tzeng, T.-C., et al. (2013) · Nature · doi:10.1038/nature11729 · Cited by 2,898 · cited 2×
“Deletion of the NALP3 inflammasome or the important effector enzyme caspase 1 resulted in a reduction of Ab plaque burden in an AD mouse model that was associated with a more ‘M2’ biased activation profile of microglia [57].”
BackgroundA Lineage of Myeloid Cells Independent of Myb and Hematopoietic Stem Cells
Schulz, C., Perdiguero, E. G., Chorro, L., Szabo-Rogers, H., Cagnard, N., Kierdorf, K., Prinz, M., Wu, B., Jacobsen, S. E. W., Pollard, J. W., et al. (2012) · Science · doi:10.1126/science.1219179 · Cited by 2,578 · cited 1×
“As microglia constitute a population of cells ontologically distinct from rapidly renewed blood monocytes [48, 72, 122], their proper function is an undeniably critical factor for CNS homeostasis, especially in light of the limited renewability of the brain.”
BackgroundVariant of TREM2 Associated with the Risk of Alzheimer's Disease
Jonsson, T., Stefansson, H., Steinberg, S., Jonsdottir, I., Jonsson, P. V., Snaedal, J., Bjornsson, S., Huttenlocher, J., Levey, A. I., Lah, J. J., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1211103 · Cited by 2,558 · cited 2×
“risk factors for AD [53, 70], microglia, the brain’s intrinsic macrophages, almost suddenly became very important cells.”
BackgroundThe NALP3 inflammasome is involved in the innate immune response to amyloid-β
Halle, A., Hornung, V., Petzold, G. C., Stewart, C. R., Monks, B. G., Reinheckel, T., Fitzgerald, K. A., Latz, E., Moore, K. J., & Golenbock, D. T. (2008) · Nature Immunology · doi:10.1038/ni.1636 · Cited by 2,441
Consortium to Establish a Registry for Alzheimer's Disease (CERAD)
Fillenbaum, G. G., & Heyman, A. (2002) · Principles and Practice of Geriatric Psychiatry · doi:10.1002/0470846410.ch42(iii · Cited by 2,410
Systemic LPS causes chronic neuroinflammation and progressive neurodegeneration
Qin, L., Wu, X., Block, M. L., Liu, Y., Breese, G. R., Hong, J., Knapp, D. J., & Crews, F. T. (2007) · Glia · doi:10.1002/glia.20467 · Cited by 2,144 · cited 1×
“While these experiments indicate the principal beneficial power of microglia, such rather unspecific, non-Ab-directed activation of microglia is certainly not a promising therapeutic strategy, as chronic stimulation of microglia with LPS was shown to cause neurodegeneration [110] per se and has also been implicated in…”
BackgroundBard, F., Cannon, C., Barbour, R., Burke, R.-L., Games, D., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., et al. (2000) · Nature Medicine · doi:10.1038/78682 · Cited by 2,012 · cited 2×
“Initial findings that antiAb antibodies can cross the blood brain barrier and activate microglia cells, indicating a direct Fc-receptor mediated mechanism of plaque clearance [8], suggest that microglia may be key for Ab-targeted treatment strategies.”
BackgroundInitiative, T. A. D. N., Hollingworth, P., CHARGE consortium, EADI1 consortium, Harold, D., Sims, R., Gerrish, A., Lambert, J.-C., Carrasquillo, M. M., Abraham, R., et al. (2011) · Nature Genetics · doi:10.1038/ng.803 · Cited by 1,997 · cited 5×
“This was reinforced when TYROBP/DAP12, the gene encoding the TREM2 adaptor protein, was found to be strongly associated with the pathophysiology of late onset AD (LOAD) as a key network regulator [169].”
BackgroundInfluentialNaj, A. C., Jun, G., Beecham, G. W., Wang, L.-S., Vardarajan, B. N., Buros, J., Gallins, P. J., Buxbaum, J. D., Jarvik, G. P., Crane, P. K., et al. (2011) · Nature Genetics · doi:10.1038/ng.801 · Cited by 1,901
Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease.
Griffin, W. S., Stanley, L. C., Ling, C., White, L., MacLeod, V, Perrot, L. J., White, C. L., & Araoz, C. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.19.7611 · Cited by 1,777 · cited 1×
“The in vivo microglial reactions in response to Ab plaques and neurofibrillary tangles include increased release of immune molecules such as interleukin (IL)-1 [52], IL-12 and IL-23 [153] or complement proteins [93], while numerous in vitro studies have demonstrated the expression and secretion of many (more) cytokine…”
BackgroundIntegrated Systems Approach Identifies Genetic Nodes and Networks in Late-Onset Alzheimer’s Disease
Zhang, B., Gaiteri, C., Bodea, L.-G., Wang, Z., McElwee, J., Podtelezhnikov, A. A., Zhang, C., Xie, T., Tran, L., Dobrin, R., et al. (2013) · Cell · doi:10.1016/j.cell.2013.03.030 · Cited by 1,657 · cited 2×
“Examples include mutations in Trem2 as risk factors for AD [53, 70], and the TREM2 adaptor molecule, TYROB/DAP12 as a central regulator associated with LOAD pathogenesis [169].”
BackgroundMicroglia Shape Adult Hippocampal Neurogenesis through Apoptosis-Coupled Phagocytosis
Sierra, A., Encinas, J. M., Deudero, J. J. P., Chancey, J. H., Enikolopov, G., Overstreet-Wadiche, L. S., Tsirka, S. E., & Maletic-Savatic, M. (2010) · Cell Stem Cell · doi:10.1016/j.stem.2010.08.014 · Cited by 1,622 · cited 1×
“Moreover, whether microglia and peripheral macrophages have functionally overlapping or distinct capabilities, especially in respect to the highly specialized roles attributed to microglia in the brain, including regulation of synaptic plasticity and neurogenesis, needs to be investigated [108, 128].”
BackgroundMicroglia emerge from erythromyeloid precursors via Pu.1- and Irf8-dependent pathways
Kierdorf, K., Erny, D., Goldmann, T., Sander, V., Schulz, C., Perdiguero, E. G., Wieghofer, P., Heinrich, A., Riemke, P., Hölscher, C., et al. (2013) · Nature Neuroscience · doi:10.1038/nn.3318 · Cited by 1,457 · cited 1×
“As microglia constitute a population of cells ontologically distinct from rapidly renewed blood monocytes [48, 72, 122], their proper function is an undeniably critical factor for CNS homeostasis, especially in light of the limited renewability of the brain.”
BackgroundNeuropathology of human Alzheimer disease after immunization with amyloid-β peptide: a case report
Nicoll, J. A. R., Wilkinson, D., Holmes, C., Steart, P., Markham, H., & Weller, R. O. (2003) · Nature Medicine · doi:10.1038/nm840 · Cited by 1,397 · cited 1×
“[86], which are viewed with caution in light of severe side effects in initial active vaccination trials, in which unwanted T-cell mediated inflammation occurred [106].”
BackgroundMcGeer, P. L., Schulzer, M., & McGeer, E. G. (1996) · Neurology · doi:10.1212/wnl.47.2.425 · Cited by 1,367
Microglial Dysfunction and Defective β-Amyloid Clearance Pathways in Aging Alzheimer's Disease Mice
Hickman, S. E., Allison, E. K., & El Khoury, J. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.0616-08.2008 · Cited by 1,329 · cited 1×
“caused by chronic (inflammatory) stimulation [63] and/or the presence of Ab [77], culminating in a state of cellular senescence [139].”
BackgroundSimard, A. R., Soulet, D., Gowing, G., Julien, J.-P., & Rivest, S. (2006) · Neuron · doi:10.1016/j.neuron.2006.01.022 · Cited by 1,265 · cited 1×
“Furthermore, Simard and colleagues proposed that bone marrow-derived myeloid cells newly recruited to the brain in an AD mouse model exhibit a specific immune reaction to b-amyloid and contain Ab within lysosomal compartments, suggesting that these cells are capable of phagocytosing plaques possibly even more efficien…”
BackgroundTakahashi, K., Rochford, C. D. P., & Neumann, H. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20041611 · Cited by 1,124 · cited 1×
“Specifically, TREM2 has been shown to influence several aspects of microglia activity including motility, T cell interactions, cytokine production and phagocytosis [65, 97, 144, 145].”
BackgroundStreit, W. J., Walter, S. A., & Pennell, N. A. (1999) · Progress in Neurobiology · doi:10.1016/s0301-0082(98)00069-0 · Cited by 1,096 · cited 1×
“While microglia activity states may correlate to some degree with morphological changes in the cell body [140], morphology certainly also has its limitations.”
BackgroundAlzheimer’s Disease Risk Gene CD33 Inhibits Microglial Uptake of Amyloid Beta
Griciuc, A., Serrano-Pozo, A., Parrado, A. R., Lesinski, A. N., Asselin, C. N., Mullin, K., Hooli, B., Choi, S. H., Hyman, B. T., & Tanzi, R. E. (2013) · Neuron · doi:10.1016/j.neuron.2013.04.014 · Cited by 1,004 · cited 1×
“Of note, CD33 was recently found to be increased in microglia in the human AD brain, and CD33 levels directly correlated with augmented insoluble Ab42 levels and enhanced amyloid plaque burden, most likely due to CD33mediated impairment of cellular uptake and clearance of Ab42 by microglia [46, 51].”
BackgroundRelationship of microglia and astrocytes to amyloid deposits of Alzheimer disease
Itagaki, S., McGeer, P. L., Akiyama, H., Zhu, S., & Selkoe, D. (1989) · Journal of Neuroimmunology · doi:10.1016/0165-5728(89)90115-x · Cited by 940 · cited 2×
“The detection of MHC-class II (HLA-DR) expression on microglia in the vicinity of Ab plaques [68, 94, 117] indicates an activation of these cells around the pathological protein deposits of AD.”
BackgroundEl Khoury, J., Toft, M., Hickman, S. E., Means, T. K., Terada, K., Geula, C., & Luster, A. D. (2007) · Nature Medicine · doi:10.1038/nm1555 · Cited by 915 · cited 1×
“Specifically, the deficiency of CCR2, a chemokine receptor expressed by myeloid cells, was reported to cause an acceleration of disease course by limiting microglia recruitment to Ab deposits [37].”
BackgroundReview: Activation patterns of microglia and their identification in the human brain
Boche, D., Perry, V. H., & Nicoll, J. A. R. (2013) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12011 · Cited by 912 · cited 1×
“Recently, the concept of classifying peripheral macrophages according to the type of T-cell mediated stimulation in ‘‘M1’’ (‘‘classically activated’’) and ‘‘M2’’ (‘‘alternatively activated’’) activation states [127] has been transferred to microglia [11] in an attempt to illustrate context-dependent microglia activati…”
Ibuprofen Suppresses Plaque Pathology and Inflammation in a Mouse Model for Alzheimer's Disease
Lim, G. P., Yang, F., Chu, T., Chen, P., Beech, W., Teter, B., Tran, T., Ubeda, O., Ashe, K. H., Frautschy, S. A., et al. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-15-05709.2000 · Cited by 884 · cited 1×
“Epidemiological studies showed that chronic use of non-steroidal anti-inflammatory drugs (NSAIDs) is associated with a reduced incidence of AD [95], and the application of certain NSAIDs to AD mouse models efficiently reduced Ab-plaque burden [82, 168].”
BackgroundRaivich, G., Bohatschek, M., Kloss, C. U. A., Werner, A., Jones, L. L., & Kreutzberg, G. W. (1999) · Brain Research Reviews · doi:10.1016/s0165-0173(99)00007-7 · Cited by 844 · cited 1×
“It appears as if there is no clear answer to this conundrum given that the response of microglia to pathological stimuli is highly dynamic and context-dependent [114].”
BackgroundMcGeer, P. L., Itagaki, S., Tago, H., & McGeer, E. G. (1987) · Neuroscience Letters · doi:10.1016/0304-3940(87)90696-3 · Cited by 836 · cited 1×
“The detection of MHC-class II (HLA-DR) expression on microglia in the vicinity of Ab plaques [68, 94, 117] indicates an activation of these cells around the pathological protein deposits of AD.”
BackgroundA phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease
Salloway, S., Sperling, R., Gilman, S., Fox, N. C., Blennow, K., Raskind, M., Sabbagh, M., Honig, L. S., Doody, R., van Dyck, C. H., et al. (2009) · Neurology · doi:10.1212/wnl.0b013e3181c67808 · Cited by 753
Rogers, J., Luber-Narod, J., Styren, S. D., & Civin, W. H. (1988) · Neurobiology of Aging · doi:10.1016/s0197-4580(88)80079-4 · Cited by 743 · cited 2×
“The detection of MHC-class II (HLA-DR) expression on microglia in the vicinity of Ab plaques [68, 94, 117] indicates an activation of these cells around the pathological protein deposits of AD.”
BackgroundExperimental autoimmune encephalomyelitis repressed by microglial paralysis
Heppner, F. L., Greter, M., Marino, D., Falsig, J., Raivich, G., Hövelmeyer, N., Waisman, A., Rülicke, T., Prinz, M., Priller, J., et al. (2005) · Nature Medicine · doi:10.1038/nm1177 · Cited by 732 · cited 1×
“Here, depletion of microglia in CD11bHSVTK transgenic mice [60] is followed by the rapid and robust recruitment of bone marrow-derived myeloid cells to the brain.”
BackgroundSelf-citationScavenger receptor-mediated adhesion of microglia to β-amyloid fibrils
Khoury, J. E., Hickman, S. E., Thomas, C. A., Cao, L., Silverstein, S. C., & Loike, J. D. (1996) · Nature · doi:10.1038/382716a0 · Cited by 727 · cited 1×
“The release of these factors by microglia is triggered more efficiently by aggregated (fibrillar) Ab, and several receptors expressed on microglia have been proposed to be critical for this signal transduction including CD36 [7, 27], class A scavenger receptor [36] and receptor for advanced glycosylation end products…”
BackgroundStreit, W. J., Braak, H., Xue, Q.-S., & Bechmann, I. (2009) · Acta Neuropathologica · doi:10.1007/s00401-009-0556-6 · Cited by 727 · cited 1×
“Morphological dystrophy of microglia is believed to characterize cellular senescence [84, 136, 137] (Fig.”
BackgroundDystrophic microglia in the aging human brain
Streit, W. J., Sammons, N. W., Kuhns, A. J., & Sparks, D. L. (2004) · Glia · doi:10.1002/glia.10319 · Cited by 705 · cited 4×
“caused by chronic (inflammatory) stimulation [63] and/or the presence of Ab [77], culminating in a state of cellular senescence [139].”
BackgroundInfluentialKitazawa, M., Oddo, S., Yamasaki, T. R., Green, K. N., & LaFerla, F. M. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.2868-05.2005 · Cited by 697 · cited 1×
“In view of the apparent link between brain inflammation and tau pathology [10, 74, 80], it is plausible that Trem2 mutations may serve to promote not only reduced amyloid clearance in early stages of disease, but also tau pathology at later stages.”
BackgroundMicroglial response to amyloid plaques in APPsw transgenic mice.
Frautschy, S. A., Yang, F., Irrizarry, M., Hyman, B. T., Saido, T. C., Hsiao, K., & Cole, G. M. (1998) · Europe PMC (PubMed Central) · Cited by 679
Paresce, D. M., Ghosh, R. N., & Maxfield, F. R. (1996) · Neuron · doi:10.1016/s0896-6273(00)80187-7 · Cited by 663 · cited 1×
“While there is overwhelming in vitro and in vivo evidence for the presence of intracellular Ab within microglia [6, 109, 118], the fate of these intracellular amyloid fibrils is still far from clear.”
BackgroundULTRASTRUCTURAL STUDIES IN ALZHEIMER'S PRESENILE DEMENTIA.
Terry, R. D., Gonatas, N. K., & WEISS, M. (1964) · PubMed Central · Cited by 644
Regulation of Tau Pathology by the Microglial Fractalkine Receptor
Bhaskar, K., Konerth, M., Kokiko-Cochran, O. N., Cardona, A., Ransohoff, R. M., & Lamb, B. T. (2010) · Neuron · doi:10.1016/j.neuron.2010.08.023 · Cited by 639 · cited 1×
“In view of the apparent link between brain inflammation and tau pathology [10, 74, 80], it is plausible that Trem2 mutations may serve to promote not only reduced amyloid clearance in early stages of disease, but also tau pathology at later stages.”
BackgroundWild-type microglia arrest pathology in a mouse model of Rett syndrome
Derecki, N. C., Cronk, J. C., Lu, Z., Xu, E., Abbott, S. B. G., Guyenet, P. G., & Kipnis, J. (2012) · Nature · doi:10.1038/nature10907 · Cited by 607 · cited 2×
“While much research still needs to be done prior to realizing such strategies in patients, recruitment of ‘fresh’ myeloid cells to the brain of irradiation-conditioned mice modeling Rett syndrome ameliorated disease pathology [31] indicating the potential therapeutic power of such strategies.”
BackgroundTGF-β1 promotes microglial amyloid-β clearance and reduces plaque burden in transgenic mice
Wyss-Coray, T., Lin, C., Yan, F., Yu, G.-Q., Rohde, M., McConlogue, L., Masliah, E., & Mucke, L. (2001) · Nature Medicine · doi:10.1038/87945 · Cited by 587
Rademakers, R., Baker, M., Nicholson, A. M., Rutherford, N. J., Finch, N., Soto-Ortolaza, A., Lash, J., Wider, C., Wojtas, A., DeJesus-Hernandez, M., et al. (2012) · Nature Genetics · doi:10.1038/ng.1027 · Cited by 571
CD33 Alzheimer's disease locus: altered monocyte function and amyloid biology
Initiative, T. A. D. N., Bradshaw, E. M., Chibnik, L. B., Keenan, B. T., Ottoboni, L., Raj, T., Tang, A., Rosenkrantz, L. L., Imboywa, S., Lee, M., et al. (2013) · Nature Neuroscience · doi:10.1038/nn.3435 · Cited by 570 · cited 1×
“Since CD33 expression is independent of age [15], it is conceivable that Cd33 represents a risk allele involved in the earliest stages of AD pathogenesis.”
BackgroundDeMattos, R. B., Bales, K. R., Cummins, D. J., Paul, S. M., & Holtzman, D. M. (2002) · Science · doi:10.1126/science.1067568 · Cited by 563 · cited 1×
“Alternatively, it has been purported that Ab-antibodies do not have to enter the CNS, but can act in the periphery by creating a so-called ‘‘peripheral sink’’ [30].”
BackgroundMicroglial Cx3cr1 knockout prevents neuron loss in a mouse model of Alzheimer's disease
Fuhrmann, M., Bittner, T., Jung, C. K. E., Burgold, S., Page, R. M., Mitteregger, G., Haass, C., LaFerla, F. M., Kretzschmar, H., & Herms, J. (2010) · Nature Neuroscience · doi:10.1038/nn.2511 · Cited by 562 · cited 1×
“Taken together, inhibition of fractalkine signaling could prove beneficial by both reducing plaque burden, and— based on the above-mentioned study [45]—ameliorating neuronal loss, although it is unclear if microglia actively contribute to neuronal death in AD or rather simply mediate the clearance of dead cells, the l…”
BackgroundLee, S., Varvel, N. H., Konerth, M. E., Xu, G., Cardona, A. E., Ransohoff, R. M., & Lamb, B. T. (2010) · The American Journal of Pathology · doi:10.2353/ajpath.2010.100265 · Cited by 522 · cited 1×
“of AD [45, 81].”
Heneka, M. T., Nadrigny, F., Regen, T., Martinez-Hernandez, A., Dumitrescu-Ozimek, L., Terwel, D., Jardanhazi-Kurutz, D., Walter, J., Kirchhoff, F., Hanisch, U.-K., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0909586107 · Cited by 518
Bertram, L., Lange, C., Mullin, K., Parkinson, M., Hsiao, M., Hogan, M. F., Schjeide, B. M. M., Hooli, B., DiVito, J., Ionita, I., et al. (2008) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2008.10.008 · Cited by 511 · cited 5×
“This was reinforced when TYROBP/DAP12, the gene encoding the TREM2 adaptor protein, was found to be strongly associated with the pathophysiology of late onset AD (LOAD) as a key network regulator [169].”
BackgroundInfluentialAge-related alterations in the dynamic behavior of microglia
Damani, M. R., Zhao, L., Fontainhas, A. M., Amaral, J., Fariss, R. N., & Wong, W. T. (2011) · Aging Cell · doi:10.1111/j.1474-9726.2010.00660.x · Cited by 504 · cited 2×
“3), which comprises changes in cellular behavior and function occurring with age and in association with protracted activation or cellular stress, as in chronic neurodegenerative disease [26, 29, 100, 107].”
BackgroundA Cell Surface Receptor Complex for Fibrillar β-Amyloid Mediates Microglial Activation
Bamberger, M. E., Harris, M. E., McDonald, D. R., Husemann, J., & Landreth, G. E. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-07-02665.2003 · Cited by 501 · cited 2×
“The release of these factors by microglia is triggered more efficiently by aggregated (fibrillar) Ab, and several receptors expressed on microglia have been proposed to be critical for this signal transduction including CD36 [7, 27], class A scavenger receptor [36] and receptor for advanced glycosylation end products…”
BackgroundCombs, C. K., Johnson, D. E., Karlo, J. C., Cannady, S. B., & Landreth, G. E. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-02-00558.2000 · Cited by 483 · cited 1×
“The Ab-mediated secretion of neurotoxic molecules by microglia [24, 25, 75, 92] and the worsening of Ab-associated pathology in experimental models in which microglia activation is enhanced provide evidence for the prior, while other studies demonstrating secretion of neuroprotective cytokines like transforming growth…”
ResultKrabbe, G., Halle, A., Matyash, V., Rinnenthal, J. L., Eom, G. D., Bernhardt, U., Miller, K. R., Prokop, S., Kettenmann, H., & Heppner, F. L. (2013) · PLoS ONE · doi:10.1371/journal.pone.0060921 · Cited by 478
Self-citationA role for TREM2 ligands in the phagocytosis of apoptotic neuronal cells by microglia
Hsieh, C. L., Koike, M., Spusta, S. C., Niemi, E. C., Yenari, M., Nakamura, M. C., & Seaman, W. E. (2009) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2009.06042.x · Cited by 475 · cited 1×
“Specifically, TREM2 has been shown to influence several aspects of microglia activity including motility, T cell interactions, cytokine production and phagocytosis [65, 97, 144, 145].”
BackgroundYan, Q., Zhang, J., Liu, H., Babu-Khan, S., Vassar, R., Biere, A. L., Citron, M., & Landreth, G. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-20-07504.2003 · Cited by 469 · cited 1×
“Epidemiological studies showed that chronic use of non-steroidal anti-inflammatory drugs (NSAIDs) is associated with a reduced incidence of AD [95], and the application of certain NSAIDs to AD mouse models efficiently reduced Ab-plaque burden [82, 168].”
BackgroundHematopoietic origin of pathological grooming in Hoxb8 mutant mice
Chen, S.-K., Tvrdik, P., Peden, E., Cho, S., Wu, S., Spangrude, G., & Capecchi, M. R. (2010) · Cell · doi:10.1016/j.cell.2010.03.055 · Cited by 450 · cited 1×
“Moreover, mutations in the colony stimulating factor 1 receptor (Csf1r) gene causing hereditary diffuse leukoencephalopathy with axonal spheroids (HDLS, [113]), and recent data from animal models of obsessive compulsive disorders [20] and autism spectrum disorders (Rett syndrome, [31]) further demonstrate the genuine…”
BackgroundProminent neurodegeneration and increased plaque formation in complement-inhibited Alzheimer's mice
Wyss-Coray, T., Yan, F., Lin, A. H.-T., Lambris, J. D., Alexander, J. J., Quigg, R. J., & Masliah, E. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.162350199 · Cited by 446
Du Yan, S., Zhu, H., Fu, J., Yan, S. F., Roher, A., Tourtellotte, W. W., Rajavashisth, T., Chen, X., Godman, G. C., Stern, D., et al. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.10.5296 · Cited by 428
Blocking TGF-β–Smad2/3 innate immune signaling mitigates Alzheimer-like pathology
Town, T., Laouar, Y., Pittenger, C., Mori, T., Szekely, C. A., Tan, J., Duman, R. S., & Flavell, R. A. (2008) · Nature Medicine · doi:10.1038/nm1781 · Cited by 422 · cited 2×
“On the other hand, blocking TGFb1 and downstream Smad2/3 signaling in CD11c positive cells also resulted in a reduction of Ab-pathology [149]; however, the latter effect was assigned to an increased influx of activated peripheral myeloid cells rather than a modulation of resident microglia activation.”
BackgroundAmyloidogenic role of cytokine TGF-β1 in transgenic mice and in Alzheimer's disease
Wyss-Coray, T., Masliah, E., Mallory, M., McConlogue, L., Johnson-Wood, K., Lin, C., & Mucke, L. (1997) · Nature · doi:10.1038/39321 · Cited by 417 · cited 2×
“Yet another example of the versatile impact of microglia-related molecules in AD is TGFb1, an important anti-inflammatory cytokine known to reduce microglia activation and shown to be elevated in AD [150, 165].”
BackgroundInhibition of IL-12/IL-23 signaling reduces Alzheimer's disease–like pathology and cognitive decline
vom Berg, J., Prokop, S., Miller, K. R., Obst, J., Kälin, R. E., Lopategui-Cabezas, I., Wegner, A., Mair, F., Schipke, C. G., Peters, O., et al. (2012) · Nature Medicine · doi:10.1038/nm.2965 · Cited by 416
Self-citationMicroglia Mediate the Clearance of Soluble Aβ through Fluid Phase Macropinocytosis
Mandrekar, S., Jiang, Q., Lee, C. Y. D., Koenigsknecht-Talboo, J., Holtzman, D. M., & Landreth, G. E. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.5572-08.2009 · Cited by 415 · cited 2×
“Microglia are also capable of engaging in pinocytosis, and it has been reported that microglia in vitro and in vivo engage in macropinocytosis of soluble Ab (sAb), which was shown to be trafficked to late endolysosomal compartments and degraded [90].”
BackgroundTakahashi, K., Prinz, M., Stagi, M., Chechneva, O., & Neumann, H. (2007) · PLoS Medicine · doi:10.1371/journal.pmed.0040124 · Cited by 414 · cited 1×
“Specifically, TREM2 has been shown to influence several aspects of microglia activity including motility, T cell interactions, cytokine production and phagocytosis [65, 97, 144, 145].”
BackgroundNeuroinflammation in Alzheimer's disease and prion disease
Eikelenboom, P., Bate, C., Van Gool, W. A., Hoozemans, J. J. M., Rozemuller, J. M., Veerhuis, R., & Williams, A. (2002) · Glia · doi:10.1002/glia.10146 · Cited by 405 · cited 1×
“Notably, such infiltrates are by and large absent from the human AD brain [35, 136].”
BackgroundA Randomized, Double-Blind, Study of Rofecoxib in Patients with Mild Cognitive Impairment
on behalf of the Rofecoxib Protocol 078 study group, Thal, L. J., Ferris, S. H., Kirby, L., Block, G. A., Lines, C. R., Yuen, E., Assaid, C., Nessly, M. L., Norman, B. A., et al. (2005) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300690 · Cited by 402
Formation and maintenance of Alzheimer's disease β-amyloid plaques in the absence of microglia
Grathwohl, S. A., Kälin, R. E., Bolmont, T., Prokop, S., Winkelmann, G., Kaeser, S. A., Odenthal, J., Radde, R., Eldh, T., Gandy, S., et al. (2009) · Nature Neuroscience · doi:10.1038/nn.2432 · Cited by 401
Self-citationCoraci, I. S., Husemann, J., Berman, J. W., Hulette, C., Dufour, J. H., Campanella, G. K., Luster, A. D., Silverstein, S. C., & El Khoury, J. B. (2002) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64354-4 · Cited by 398 · cited 2×
“The release of these factors by microglia is triggered more efficiently by aggregated (fibrillar) Ab, and several receptors expressed on microglia have been proposed to be critical for this signal transduction including CD36 [7, 27], class A scavenger receptor [36] and receptor for advanced glycosylation end products…”
BackgroundVarnum, M. M., & Ikezu, T. (2012) · Archivum Immunologiae et Therapiae Experimentalis · doi:10.1007/s00005-012-0181-2 · Cited by 394 · cited 2×
“These findings are often viewed as evidence that microglia are contributing to disease progression by producing neurotoxic substances, especially in later stages of disease [151].”
BackgroundExpression profiles for macrophage alternative activation genes in AD and in mouse models of AD.
(2006) · Journal of Neuroinflammation · doi:10.1186/1742-2094-3-27 · Cited by 393 · cited 1×
“Although microglia express markers for both classical and alternative activation in AD [23], there seems to be a consensus that during the course of disease, similar to normal aging, microglia undergo a switch from a neuroprotective to a more classically activated phenotype at later stages of disease [69, 151].”
BackgroundSheng, J. (2003) · Neurobiology of Disease · doi:10.1016/s0969-9961(03)00069-x · Cited by 388 · cited 1×
“While these experiments indicate the principal beneficial power of microglia, such rather unspecific, non-Ab-directed activation of microglia is certainly not a promising therapeutic strategy, as chronic stimulation of microglia with LPS was shown to cause neurodegeneration [110] per se and has also been implicated in…”
BackgroundActivation of the classical complement pathway in brain tissue of Alzheimer patients
McGeer, P. L., Akiyama, H., Itagaki, S., & McGeer, E. G. (1989) · Neuroscience Letters · doi:10.1016/0304-3940(89)90843-4 · Cited by 383 · cited 1×
“The in vivo microglial reactions in response to Ab plaques and neurofibrillary tangles include increased release of immune molecules such as interleukin (IL)-1 [52], IL-12 and IL-23 [153] or complement proteins [93], while numerous in vitro studies have demonstrated the expression and secretion of many (more) cytokine…”
BackgroundJimenez, S., Baglietto-Vargas, D., Caballero, C., Moreno-Gonzalez, I., Torres, M., Sanchez-Varo, R., Ruano, D., Vizuete, M., Gutierrez, A., & Vitorica, J. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.3024-08.2008 · Cited by 383 · cited 1×
“Although microglia express markers for both classical and alternative activation in AD [23], there seems to be a consensus that during the course of disease, similar to normal aging, microglia undergo a switch from a neuroprotective to a more classically activated phenotype at later stages of disease [69, 151].”
BackgroundInflammatory repertoire of Alzheimer's disease and nondemented elderly microglia in vitro
Lue, L., Rydel, R., Brigham, E. F., Yang, L., Hampel, H., Murphy, G. M., Brachova, L., Yan, S., Walker, D. G., Shen, Y., et al. (2001) · Glia · doi:10.1002/glia.1072 · Cited by 382
Microglia and inflammatory mechanisms in the clearance of amyloid β peptide
Rogers, J., Strohmeyer, R., Kovelowski, C. J., & Li, R. (2002) · Glia · doi:10.1002/glia.10153 · Cited by 381 · cited 2×
“While there is overwhelming in vitro and in vivo evidence for the presence of intracellular Ab within microglia [6, 109, 118], the fate of these intracellular amyloid fibrils is still far from clear.”
BackgroundNaproxen and celecoxib do not prevent AD in early results from a randomized controlled trial
ADAPT Research Group (2007) · Neurology · doi:10.1212/01.wnl.0000260269.93245.d2 · Cited by 354 · cited 1×
“While the failure of NSAIDs to prevent AD in randomized prospective clinical trials [2, 87, 131, 148] has put a hold on the pursuit of this therapeutic avenue, a better understanding of differential effects of NSAIDs in early and late phases of disease [16], delineation of mechanisms of action of certain NSAIDs beyond…”
BackgroundCombs, C. K., Johnson, D. E., Cannady, S. B., Lehman, T. M., & Landreth, G. E. (1999) · The Journal of Neuroscience · doi:10.1523/jneurosci.19-03-00928.1999 · Cited by 352 · cited 1×
“The Ab-mediated secretion of neurotoxic molecules by microglia [24, 25, 75, 92] and the worsening of Ab-associated pathology in experimental models in which microglia activation is enhanced provide evidence for the prior, while other studies demonstrating secretion of neuroprotective cytokines like transforming growth…”
ResultMildner, A., Schlevogt, B., Kierdorf, K., Böttcher, C., Erny, D., Kummer, M. P., Quinn, M., Brück, W., Bechmann, I., Heneka, M. T., et al. (2011) · The Journal of Neuroscience · doi:10.1523/jneurosci.6209-10.2011 · Cited by 351 · cited 1×
“the effect to reduced microglia activation [103], while the other demonstrated that perivascular macrophages, rather than resident microglia, mediate the observed effect [99] indicating that effects other than purely physical accumulation of resident microglia next to Ab-plaques confers benefit.”
BackgroundWeldon, D. T., Rogers, S. D., Ghilardi, J. R., Finke, M. P., Cleary, J. P., O’Hare, E., Esler, W. P., Maggio, J. E., & Mantyh, P. W. (1998) · The Journal of Neuroscience · doi:10.1523/jneurosci.18-06-02161.1998 · Cited by 348
Association of Microglia with Amyloid Plaques in Brains of APP23 Transgenic Mice
Stalder, M., Phinney, A., Probst, A., Sommer, B., Staufenbiel, M., & Jucker, M. (1999) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)65423-5 · Cited by 345 · cited 1×
“plaques have been extensively confirmed in both humans [117, 142] and animal models of AD [43, 135].”
BackgroundAbsence of C1q Leads to Less Neuropathology in Transgenic Mouse Models of Alzheimer's Disease
Fonseca, M. I., Zhou, J., Botto, M., & Tenner, A. J. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.0901-04.2004 · Cited by 345
Njie, E. G., Boelen, E., Stassen, F. R., Steinbusch, H. W. M., Borchelt, D. R., & Streit, W. J. (2012) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.05.008 · Cited by 335 · cited 2×
“3), which comprises changes in cellular behavior and function occurring with age and in association with protracted activation or cellular stress, as in chronic neurodegenerative disease [26, 29, 100, 107].”
BackgroundMicroglia and Alzheimer's disease pathogenesis
Streit, W. J. (2004) · Journal of Neuroscience Research · doi:10.1002/jnr.20093 · Cited by 335 · cited 2×
“Notably, such infiltrates are by and large absent from the human AD brain [35, 136].”
BackgroundExtended results of the Alzheimer's disease anti‐inflammatory prevention trial
Breitner, J. C., Baker, L. D., Montine, T. J., Meinert, C. L., Lyketsos, C. G., Ashe, K. H., Brandt, J., Craft, S., Evans, D. E., Green, R. C., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2010.12.014 · Cited by 328
Yamanaka, M., Ishikawa, T., Griep, A., Axt, D., Kummer, M. P., & Heneka, M. T. (2012) · The Journal of Neuroscience · doi:10.1523/jneurosci.1569-12.2012 · Cited by 326
Maier, M., Peng, Y., Jiang, L., Seabrook, T. J., Carroll, M. C., & Lemere, C. A. (2008) · Journal of Neuroscience · doi:10.1523/jneurosci.0829-08.2008 · Cited by 323
Amyloid Fibrils Activate Tyrosine Kinase-Dependent Signaling and Superoxide Production in Microglia
McDonald, D. R., Brunden, K. R., & Landreth, G. E. (1997) · The Journal of Neuroscience · doi:10.1523/jneurosci.17-07-02284.1997 · Cited by 317 · cited 1×
“The Ab-mediated secretion of neurotoxic molecules by microglia [24, 25, 75, 92] and the worsening of Ab-associated pathology in experimental models in which microglia activation is enhanced provide evidence for the prior, while other studies demonstrating secretion of neuroprotective cytokines like transforming growth…”
ResultAdolfsson, O., Pihlgren, M., Toni, N., Varisco, Y., Buccarello, A. L., Antoniello, K., Lohmann, S., Piorkowska, K., Gafner, V., Atwal, J. K., et al. (2012) · Journal of Neuroscience · doi:10.1523/jneurosci.4742-11.2012 · Cited by 317
Microglia are the major cell type expressing MHC class II in human white matter
Hayes, G. M., Woodroofe, M. N., & Cuzner, M. L. (1987) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(87)90218-8 · Cited by 302 · cited 1×
“However, while increased MHCclass II antigen expression does accompany cellular activation [5, 130, 138], the expression of this marker is not limited to activated microglia cells [28, 56, 138].”
BackgroundWilcock, D. M., Rojiani, A., Rosenthal, A., Levkowitz, G., Subbarao, S., Alamed, J., Wilson, D., Wilson, N., Freeman, M. J., Gordon, M. N., et al. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.1090-04.2004 · Cited by 299 · cited 1×
“While there is undeniable evidence that Ab-targeted vaccination activates microglia cells [76, 158–160] and induces uptake of Ab by microglia [90, 156], the overall importance of microglia for Ab-targeted immunotherapy has been questioned based on only partially limited antibody-induced Ab clearance in AD mice harbori…”
BackgroundRichard, K. L., Filali, M., Préfontaine, P., & Rivest, S. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.1146-08.2008 · Cited by 298
LPS- induced inflammation exacerbates phospho-tau pathology in rTg4510 mice
Lee, D. C., Rizer, J., Selenica, M.-L. B., Reid, P., Kraft, C., Johnson, A., Blair, L., Gordon, M. N., Dickey, C. A., & Morgan, D. (2010) · Journal of Neuroinflammation · doi:10.1186/1742-2094-7-56 · Cited by 293 · cited 1×
“In view of the apparent link between brain inflammation and tau pathology [10, 74, 80], it is plausible that Trem2 mutations may serve to promote not only reduced amyloid clearance in early stages of disease, but also tau pathology at later stages.”
BackgroundStreit, W. J., Graeber, M. B., & Kreutzberg, G. W. (1989) · Experimental Neurology · doi:10.1016/0014-4886(89)90111-8 · Cited by 287 · cited 1×
“However, while increased MHCclass II antigen expression does accompany cellular activation [5, 130, 138], the expression of this marker is not limited to activated microglia cells [28, 56, 138].”
BackgroundHYMAN, B. T., MARZLOFF, K., & ARRIAGADA, P. V. (1993) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/00005072-199311000-00006 · Cited by 276 · cited 1×
“Moreover, the course of AD progression demonstrates that apparently, microglia action does not suffice to contain or stop pathology [67].”
BackgroundFrackowiak, J., Wisniewski, H. M., Wegiel, J., Merz, G. S., Iqbal, K., & Wang, K. C. (1992) · Acta Neuropathologica · doi:10.1007/bf00227813 · Cited by 276 · cited 2×
“The first hints that stimulation of microglia cells can trigger enhanced clearance of Ab came from early histological studies in AD patients [40, 161] and animal models [126] in which intracellular Ab was observed in microglia cells.”
BackgroundSong, M., Jin, J., Lim, J.-E., Kou, J., Pattanayak, A., Rehman, J. A., Kim, H.-D., Tahara, K., Lalonde, R., & Fukuchi, K.-I. (2011) · Journal of Neuroinflammation · doi:10.1186/1742-2094-8-92 · Cited by 273
Fonseca, M. I., Ager, R. R., Chu, S.-H., Yazan, O., Sanderson, S. D., LaFerla, F. M., Taylor, S. M., Woodruff, T. M., & Tenner, A. J. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0901005 · Cited by 268
Lopes, K. O., Sparks, D. L., & Streit, W. J. (2008) · Glia · doi:10.1002/glia.20678 · Cited by 262
Michaud, J.-P., Hallé, M., Lampron, A., Thériault, P., Préfontaine, P., Filali, M., Tribout-Jover, P., Lanteigne, A.-M., Jodoin, R., Cluff, C., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1215165110 · Cited by 252 · cited 1×
“through stimulating phagocytic capacity using the Toll-like receptor (TLR)4 agonist monophosphoryl lipid A (MPL)— known to be safe for use in humans—, which resulted in an amelioration of AD-like pathology in an in vivo murine setting [98].”
MethodComplement and cytokine gene expression in cultured microglia derived from postmortem human brains
Walker, D. G., Kim, S. U., & McGeer, P. L. (1995) · Journal of Neuroscience Research · doi:10.1002/jnr.490400407 · Cited by 248 · cited 1×
“In addition, complement proteins and activation of the complement cascade are crucial players in Ab-mediated microglia activation [124, 141, 154].”
BackgroundTREM2 is upregulated in amyloid plaque-associated microglia in aged APP23 transgenic mice
Frank, S., Burbach, G. J., Bonin, M., Walter, M., Streit, W., Bechmann, I., & Deller, T. (2008) · Glia · doi:10.1002/glia.20710 · Cited by 247 · cited 1×
“Furthermore, TREM2 expression has been demonstrated on plaque-associated microglia in AD mouse models [41, 97] and given its positive correlation with amyloid phagocytosis and overall non-inflammatory nature, impaired microglia TREM2 signaling is likely to result in decreased Ab clearance and enhanced inflammation in…”
BackgroundUltrastructural Studies of the Cells Forming Amyloid Fibers in Classical Plaques
Wisniewski, H. M., Wegiel, J., Wang, K. C., Kujawa, M., & Lach, B. (1989) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/s0317167100029887 · Cited by 244 · cited 1×
“1) exhibiting an intimate interaction of their processes with Ab fibrils [68, 147, 162].”
BackgroundMartín-Moreno, A. M., Brera, B., Spuch, C., Carro, E., García-García, L., Delgado, M., Pozo, M. A., Innamorato, N. G., Cuadrado, A., & de Ceballos, M. L. (2012) · Journal of Neuroinflammation · doi:10.1186/1742-2094-9-8 · Cited by 241
Plasma multianalyte profiling in mild cognitive impairment and Alzheimer disease
Hu, W. T., Holtzman, D. M., Fagan, A. M., Shaw, L. M., Perrin, R., Arnold, S. E., Grossman, M., Xiong, C., Craig-Schapiro, R., Clark, C. M., et al. (2012) · Neurology · doi:10.1212/wnl.0b013e318266fa70 · Cited by 241
Microglial repopulation model reveals a robust homeostatic process for replacing CNS myeloid cells
Varvel, N. H., Grathwohl, S. A., Baumann, F., Liebig, C., Bosch, A., Brawek, B., Thal, D. R., Charo, I. F., Heppner, F. L., Aguzzi, A., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1210150109 · Cited by 240 · cited 1×
“pool may serve to significantly reduce or control plaque burden in AD patients, we and others [152] have developed”
BackgroundSelf-citationWilcock, D. M., DiCarlo, G., Henderson, D., Jackson, J., Clarke, K., Ugen, K. E., Gordon, M. N., & Morgan, D. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-09-03745.2003 · Cited by 232 · cited 1×
“While there is undeniable evidence that Ab-targeted vaccination activates microglia cells [76, 158–160] and induces uptake of Ab by microglia [90, 156], the overall importance of microglia for Ab-targeted immunotherapy has been questioned based on only partially limited antibody-induced Ab clearance in AD mice harbori…”
BackgroundTransforming growth factor-β1 is in plaques in Alzheimer and Down pathologies
van der Wal, E. A., Gómez-Pinilla, F., & Cotman, C. W. (1993) · NeuroReport · doi:10.1097/00001756-199301000-00018 · Cited by 231 · cited 1×
“Yet another example of the versatile impact of microglia-related molecules in AD is TGFb1, an important anti-inflammatory cytokine known to reduce microglia activation and shown to be elevated in AD [150, 165].”
BackgroundWyss-Coray, T., Lin, C., Sanan, D. A., Mucke, L., & Masliah, E. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64713-x · Cited by 224 · cited 1×
“Experimental overexpression of TGFb1 increases vascular Ab-deposition and microvascular damage [163, 165], while reducing Ab-plaque burden by enhancing microglia-mediated clearance of Ab [164].”
BackgroundMinocycline affects microglia activation, Aβ deposition, and behavior in APP‐tg mice
Seabrook, T. J., Jiang, L., Maier, M., & Lemere, C. A. (2006) · Glia · doi:10.1002/glia.20338 · Cited by 223
Intrahippocampal LPS injections reduce Aβ load in APP+PS1 transgenic mice
DiCarlo, G. (2001) · Neurobiology of Aging · doi:10.1016/s0197-4580(01)00292-5 · Cited by 223
Boissonneault, V., Filali, M., Lessard, M., Relton, J., Wong, G., & Rivest, S. (2008) · Brain · doi:10.1093/brain/awn331 · Cited by 221
Frenkel, D., Wilkinson, K., Zhao, L., Hickman, S. E., Means, T. K., Puckett, L., Farfara, D., Kingery, N. D., Weiner, H. L., & El Khoury, J. (2013) · Nature Communications · doi:10.1038/ncomms3030 · Cited by 214
Kim, W. S., Li, H., Ruberu, K., Chan, S., Elliott, D. A., Low, J. K., Cheng, D., Karl, T., & Garner, B. (2013) · The Journal of Neuroscience · doi:10.1523/jneurosci.4165-12.2013 · Cited by 208
Naert, G., & Rivest, S. (2011) · The Journal of Neuroscience · doi:10.1523/jneurosci.0299-11.2011 · Cited by 207 · cited 1×
“the effect to reduced microglia activation [103], while the other demonstrated that perivascular macrophages, rather than resident microglia, mediate the observed effect [99] indicating that effects other than purely physical accumulation of resident microglia next to Ab-plaques confers benefit.”
BackgroundWilcock, D. M., Munireddy, S. K., Rosenthal, A., Ugen, K. E., Gordon, M. N., & Morgan, D. (2004) · Neurobiology of Disease · doi:10.1016/j.nbd.2003.09.015 · Cited by 202
Neuronal expression of mRNAs for complement proteins of the classical pathway in Alzheimer brain
Shen, Y., Li, R., McGeer, E. G., & McGeer, P. L. (1997) · Brain Research · doi:10.1016/s0006-8993(97)00850-0 · Cited by 195 · cited 1×
“In addition, complement proteins and activation of the complement cascade are crucial players in Ab-mediated microglia activation [124, 141, 154].”
BackgroundNeuroinflammatory phenotype in early Alzheimer's disease
Sudduth, T. L., Schmitt, F. A., Nelson, P. T., & Wilcock, D. M. (2013) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2012.09.012 · Cited by 195 · cited 1×
“Importantly, CSF expression of microglia-derived p40, a common subunit of IL-12 and IL-23, was also shown to correlate with a worsening of cognitive performance in AD patients [153] and was found to be increased in the plasma and CNS tissue of subjects suffering from AD [66, 143] indicating the therapeutic power of bl…”
BackgroundStyren, S. D., Civin, W. H., & Rogers, J. (1990) · Experimental Neurology · doi:10.1016/0014-4886(90)90054-v · Cited by 191
Frautschy, S. A., Cole, G. M., & Baird, A. (1992) · PubMed · Cited by 176
Time-dependent reduction in Aβ levels after intracranial LPS administration in APP transgenic mice
Herber, D. L., Roth, L. M., Wilson, D. H., Wilson, N., Mason, J. E., Morgan, D., & Gordon, M. N. (2004) · Experimental Neurology · doi:10.1016/j.expneurol.2004.07.007 · Cited by 170 · cited 1×
“general microglia activation [17], into the brains of mice with AD-like pathology, which resulted in a reduction of Ab-plaque burden [61, 62].”
BackgroundMeda, L., Baron, P., Prat, E., Scarpini, E. A., Scarlato, G., Cassatella, M. A., & Rossi, F. (1999) · Journal of Neuroimmunology · doi:10.1016/s0165-5728(98)00188-x · Cited by 170
Gene expression profiling of amyloid beta peptide-stimulated human post-mortem brain microglia
Walker, D. G., Lue, L. F., & Beach, T. G. (2001) · Neurobiology of Aging · doi:10.1016/s0197-4580(01)00306-2 · Cited by 167
Sanchez-Ramos, J., Song, S., Sava, V., Catlow, B., Lin, X., Mori, T., Cao, C., & Arendash, G. W. (2009) · Neuroscience · doi:10.1016/j.neuroscience.2009.05.071 · Cited by 167
Herber, D. L., Mercer, M., Roth, L. M., Symmonds, K., Maloney, J. L., Wilson, N., Freeman, M. J., Morgan, D., & Gordon, M. N. (2007) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-007-9069-z · Cited by 167 · cited 1×
“general microglia activation [17], into the brains of mice with AD-like pathology, which resulted in a reduction of Ab-plaque burden [61, 62].”
BackgroundAkiyama, H., Itagaki, S., & McGeer, P. L. (1988) · Journal of Neuroscience Research · doi:10.1002/jnr.490200202 · Cited by 160 · cited 1×
“However, while increased MHCclass II antigen expression does accompany cellular activation [5, 130, 138], the expression of this marker is not limited to activated microglia cells [28, 56, 138].”
BackgroundMizuno, T., Doi, Y., Mizoguchi, H., Jin, S., Noda, M., Sonobe, Y., Takeuchi, H., & Suzumura, A. (2011) · The American Journal of Pathology · doi:10.1016/j.ajpath.2011.06.011 · Cited by 159
Koenigsknecht-Talboo, J., Meyer-Luehmann, M., Parsadanian, M., Garcia-Alloza, M., Finn, M. B., Hyman, B. T., Bacskai, B. J., & Holtzman, D. M. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.4147-08.2008 · Cited by 149
Buttini, M., Limonta, S., & Boddeke, H. W. G. M. (1996) · Neurochemistry International · doi:10.1016/0197-0186(95)00141-7 · Cited by 144
Long-Term Efficacy and Safety of Celecoxib in Alzheimer’s Disease
Soininen, H., West, C., Robbins, J., & Niculescu, L. (2007) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000096588 · Cited by 143 · cited 1×
“While the failure of NSAIDs to prevent AD in randomized prospective clinical trials [2, 87, 131, 148] has put a hold on the pursuit of this therapeutic avenue, a better understanding of differential effects of NSAIDs in early and late phases of disease [16], delineation of mechanisms of action of certain NSAIDs beyond…”
BackgroundDoi, Y., Mizuno, T., Maki, Y., Jin, S., Mizoguchi, H., Ikeyama, M., Doi, M., Michikawa, M., Takeuchi, H., & Suzumura, A. (2009) · The American Journal of Pathology · doi:10.2353/ajpath.2009.090418 · Cited by 135
Melchior, B., Garcia, A. E., Hsiung, B.-K., Lo, K. M., Doose, J. M., Thrash, J. C., Stalder, A. K., Staufenbiel, M., Neumann, H., & Carson, M. J. (2010) · ASN Neuro · doi:10.1042/an20100010 · Cited by 134 · cited 2×
“Specifically, TREM2 has been shown to influence several aspects of microglia activity including motility, T cell interactions, cytokine production and phagocytosis [65, 97, 144, 145].”
BackgroundThe effects of aging, injury and disease on microglial function: a case for cellular senescence
Miller, K. R., & Streit, W. J. (2007) · Neuron Glia Biology · doi:10.1017/s1740925x08000136 · Cited by 134 · cited 3×
“While in vitro experiments and animals with AD-like pathology undoubtedly mimic only certain aspects of the in vivo situation in human AD, where microglia have been described to undergo cellular senescence [100, 139], recent findings have cleared the blurry picture of microglia in AD: microglia reactivity in early sta…”
BackgroundSelf-citationChoi, S., Aid, S., Caracciolo, L., Sakura Minami, S., Niikura, T., Matsuoka, Y., Turner, R. S., Mattson, M. P., & Bosetti, F. (2013) · Journal of Neurochemistry · doi:10.1111/jnc.12059 · Cited by 132
Boyd, T. D., Bennett, S. P., Mori, T., Governatori, N., Runfeldt, M., Norden, M., Padmanabhan, J., Neame, P., Wefes, I., Sanchez-Ramos, J., et al. (2010) · Journal of Alzheimer's Disease · doi:10.3233/jad-2010-091471 · Cited by 128
Detection of complement alternative pathway mRNA and proteins in the Alzheimer’s disease brain
Strohmeyer, R., Shen, Y., & Rogers, J. (2000) · Molecular Brain Research · doi:10.1016/s0169-328x(00)00149-2 · Cited by 124 · cited 1×
“In addition, complement proteins and activation of the complement cascade are crucial players in Ab-mediated microglia activation [124, 141, 154].”
BackgroundStalder, M., Deller, T., Staufenbiel, M., & Jucker, M. (2001) · Neurobiology of Aging · doi:10.1016/s0197-4580(01)00209-3 · Cited by 118 · cited 1×
“On the other hand, others fail to demonstrate a clear association of Ab-fibrils within the phagosome in vivo [134].”
BackgroundWang, A., Das, P., Switzer, R. C., Golde, T. E., & Jankowsky, J. L. (2011) · The Journal of Neuroscience · doi:10.1523/jneurosci.5077-10.2011 · Cited by 118 · cited 1×
“While there is undeniable evidence that Ab-targeted vaccination activates microglia cells [76, 158–160] and induces uptake of Ab by microglia [90, 156], the overall importance of microglia for Ab-targeted immunotherapy has been questioned based on only partially limited antibody-induced Ab clearance in AD mice harbori…”
BackgroundPhagocytosis of ?/A4 amyloid fibrils of the neuritic neocortical plaques
Wisniewski, H. M., Barcikowska, M., & Kida, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00310142 · Cited by 109 · cited 1×
“The first hints that stimulation of microglia cells can trigger enhanced clearance of Ab came from early histological studies in AD patients [40, 161] and animal models [126] in which intracellular Ab was observed in microglia cells.”
BackgroundFractalkine overexpression suppresses tau pathology in a mouse model of tauopathy
Nash, K. R., Lee, D. C., Hunt, J. B., Morganti, J. M., Selenica, M.-L., Moran, P., Reid, P., Brownlow, M., Guang-Yu Yang, C., Savalia, M., et al. (2013) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2012.12.011 · Cited by 108 · cited 1×
“onstrates that overexpression of CX3CL1 can ameliorate tau pathology in a mouse model [105].”
BackgroundReed-Geaghan, E. G., Reed, Q. W., Cramer, P. E., & Landreth, G. E. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.2637-10.2010 · Cited by 104 · cited 1×
“Findings in which the deletion of CD14 attenuated plaque pathology by altering the inflammatory response of microglia in the brain demonstrate the interventional potential of the modulation of microglia activation [115].”
BackgroundInflammation and cerebral amyloidosis are disconnected in an animal model of Alzheimer's disease
Quinn, J. (2003) · Journal of Neuroimmunology · doi:10.1016/s0165-5728(03)00037-7 · Cited by 102
Effect of aging on the microglial response to peripheral nerve injury
Conde, J. R., & Streit, W. J. (2006) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2005.07.012 · Cited by 86 · cited 1×
“3), which comprises changes in cellular behavior and function occurring with age and in association with protracted activation or cellular stress, as in chronic neurodegenerative disease [26, 29, 100, 107].”
BackgroundÅkerblom, M., Sachdeva, R., Quintino, L., Wettergren, E. E., Chapman, K. Z., Manfre, G., Lindvall, O., Lundberg, C., & Jakobsson, J. (2013) · Nature Communications · doi:10.1038/ncomms2801 · Cited by 85 · cited 1×
“When considering solutions to microglia dysfunction conferred by genetic mutations, besides approaches utilizing cell replacement strategies (as outlined earlier), microglia-specific gene therapy—an emerging, yet still relatively unexplored avenue of research [3]—may prove promising.”
MethodFormation and maintenance of Alzheimer’s disease beta-amyloid plaques in the absence of microglia
Grathwohl, S., Kälin, R. E., Bolmont, T., Prokop, S., Winkelmann, G., Kaeser, S. A., Odenthal, J., Radde, R., Eldh, T., Gandy, S., et al. (2010) · e-Neuroforum · doi:10.1515/nf-2010-0107 · Cited by 84 · cited 1×
“This reduced functional viability may explain why temporary ablation of microglia for up to 30 days in an AD mouse model did not alter the formation or maintenance of Ab burden [50].”
BackgroundSelf-citationShigematsu, K., McGeer, P. L., Walker, D. G., Ishii, T., & McGeer, E. G. (1992) · Journal of Neuroscience Research · doi:10.1002/jnr.490310306 · Cited by 83 · cited 3×
“The first hints that stimulation of microglia cells can trigger enhanced clearance of Ab came from early histological studies in AD patients [40, 161] and animal models [126] in which intracellular Ab was observed in microglia cells.”
BackgroundCameron, B., Tse, W., Lamb, R., Li, X., Lamb, B. T., & Landreth, G. E. (2012) · The Journal of Neuroscience · doi:10.1523/jneurosci.1729-12.2012 · Cited by 73
Microglia as Dynamic and Essential Components of the Amyloid Hypothesis
Gandy, S., & Heppner, F. L. (2013) · Neuron · doi:10.1016/j.neuron.2013.05.007 · Cited by 73 · cited 1×
“Of note, CD33 was recently found to be increased in microglia in the human AD brain, and CD33 levels directly correlated with augmented insoluble Ab42 levels and enhanced amyloid plaque burden, most likely due to CD33mediated impairment of cellular uptake and clearance of Ab42 by microglia [46, 51].”
BackgroundSelf-citationHa, T.-Y., Chang, K.-A., Kim, J. A., Kim, H.-S., Kim, S., Chong, Y. H., & Suh, Y.-H. (2010) · PLoS ONE · doi:10.1371/journal.pone.0008840 · Cited by 73
Craggs, R. I., & Webster, H. D. F. (1985) · Acta Neuropathologica · doi:10.1007/bf00690828 · Cited by 70 · cited 1×
“However, while increased MHCclass II antigen expression does accompany cellular activation [5, 130, 138], the expression of this marker is not limited to activated microglia cells [28, 56, 138].”
BackgroundKummer, M. P., Vogl, T., Axt, D., Griep, A., Vieira-Saecker, A., Jessen, F., Gelpi, E., Roth, J., & Heneka, M. T. (2012) · The Journal of Neuroscience · doi:10.1523/jneurosci.1504-12.2012 · Cited by 70
MyD88 Deficiency Ameliorates β-Amyloidosis in an Animal Model of Alzheimer's Disease
Lim, J.-E., Kou, J., Song, M., Pattanayak, A., Jin, J., Lalonde, R., & Fukuchi, K.-I. (2011) · The American Journal of Pathology · doi:10.1016/j.ajpath.2011.05.045 · Cited by 63
Lue, L., & Walker, D. G. (2002) · Journal of Neuroscience Research · doi:10.1002/jnr.10422 · Cited by 56 · cited 1×
“[86], which are viewed with caution in light of severe side effects in initial active vaccination trials, in which unwanted T-cell mediated inflammation occurred [106].”
BackgroundManczak, M., Mao, P., Nakamura, K., Bebbington, C., Park, B., & Reddy, P. H. (2009) · Human Molecular Genetics · doi:10.1093/hmg/ddp331 · Cited by 56
Keene, C. D., Chang, R. C., López-Yglesias, A. H., Shalloway, B. R., Sokal, I., Li, X., Reed, P., Keene, L. M., Montine, K. S., BREYER, R. M., et al. (2010) · American Journal Of Pathology · doi:10.2353/ajpath.2010.090840 · Cited by 55
A limited role for microglia in antibody mediated plaque clearance in APP mice
García-Alloza, M., Ferrara, B. J., Dodwell, S. A., Hickey, G. A., Hyman, B. T., & Bacskai, B. J. (2007) · Neurobiology of Disease · doi:10.1016/j.nbd.2007.07.019 · Cited by 50 · cited 1×
“While there is undeniable evidence that Ab-targeted vaccination activates microglia cells [76, 158–160] and induces uptake of Ab by microglia [90, 156], the overall importance of microglia for Ab-targeted immunotherapy has been questioned based on only partially limited antibody-induced Ab clearance in AD mice harbori…”
BackgroundHeneka, M. T., Kummer, M. P., Weggen, S., Bulic, B., Multhaup, G., Munter, L. M., Hüll, M., Pflanzner, T., & Pietrzik, C. U. (2011) · Current Alzheimer Research · doi:10.2174/156720511795256099 · Cited by 46 · cited 1×
“While the failure of NSAIDs to prevent AD in randomized prospective clinical trials [2, 87, 131, 148] has put a hold on the pursuit of this therapeutic avenue, a better understanding of differential effects of NSAIDs in early and late phases of disease [16], delineation of mechanisms of action of certain NSAIDs beyond…”
BackgroundQuantitative and Mechanistic Studies of Aβ Immunotherapy
Golde, T., Das, P., & Levites, Y. (2009) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/187152709787601830 · Cited by 46 · cited 1×
“Following the seminal finding that active vaccination against Ab can reduce plaque burden in AD mouse models [121], several clinical trials in early or late phases of AD have been initiated despite the fact that the exact mechanism explaining how antibodies against Ab reduce plaque burden is still far from clear [49].”
BackgroundSong, M., Xiong, J., Wang, Y., Tang, J., Zhang, B., & Bai, Y. (2012) · PLoS ONE · doi:10.1371/journal.pone.0029790 · Cited by 41
Cimino, P. J., Yang, Y., Li, X., Hemingway, J. F., Cherne, M. K., Khademi, S. B., Fukui, Y., Montine, K. S., Montine, T. J., & Keene, C. D. (2013) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2013.01.002 · Cited by 36
Smetanka, A. M., Yee, K. T., & Lund, R. D. (1990) · Brain Research · doi:10.1016/0006-8993(90)91564-w · Cited by 26 · cited 1×
“However, while increased MHCclass II antigen expression does accompany cellular activation [5, 130, 138], the expression of this marker is not limited to activated microglia cells [28, 56, 138].”
BackgroundAisen, P. S., Schafer, K. A., Grundman, M., Pfeiffer, E., Sano, M., Davis, K. L., Farlow, M. R., Jin, S., Thomas, R. G., Thal, L. J., et al. (2003) · JAMA · doi:10.1001/jama.289.21.2819 · Cited by 5 · cited 1×
“While the failure of NSAIDs to prevent AD in randomized prospective clinical trials [2, 87, 131, 148] has put a hold on the pursuit of this therapeutic avenue, a better understanding of differential effects of NSAIDs in early and late phases of disease [16], delineation of mechanisms of action of certain NSAIDs beyond…”
BackgroundTátrai, E., Brózik, M., Kovačíková, Z., & Horváth, M. (2005) · Biomedical Papers · doi:10.5507/bp.2005.058 · Cited by 5 · cited 1×
“Thus, sheer uptake of Ab by microglia does not clarify the possible fate of intra-microglial Ab, which may be similar to the frustrated response of alveolar macrophages to asbestos fibers [146].”
BackgroundKlegeris (1997) · doi:10.1002/(sici)1097-4547(19970715)49:2
Ard (1996) · doi:10.1002/(sici)1097-4547(19960115)43:2
Cited by
Immune attack: the role of inflammation in Alzheimer disease
Heppner, F. L., Ransohoff, R. M., & Becher, B. (2015) · Nature Reviews Neuroscience · doi:10.1038/nrn3880 · Cited by 2,134
Self-citationReactive Gliosis and the Multicellular Response to CNS Damage and Disease
Burda, J. E., & Sofroniew, M. V. (2014) · Neuron · doi:10.1016/j.neuron.2013.12.034 · Cited by 1,438
Neutrophils promote Alzheimer's disease–like pathology and cognitive decline via LFA-1 integrin
Zenaro, E., Pietronigro, E., Bianca, V. D., Piacentino, G., Marongiu, L., Budui, S., Turano, E., Rossi, B., Angiari, S., Dusi, S., et al. (2015) · Nature Medicine · doi:10.1038/nm.3913 · Cited by 865
Phagocytosis of Microglia in the Central Nervous System Diseases
Fu, R., Shen, Q., Xu, P., Luo, J. J., & Tang, Y. (2014) · Molecular Neurobiology · doi:10.1007/s12035-013-8620-6 · Cited by 652
“Activated microglia are observed in nearly all kinds of neurological diseases, including neurodegenerative diseases such as Alzheimer’s disease (AD) [5], Parkinson’s disease (PD) [6], and amyotrophic lateral sclerosis (ALS) [7]; infectious and inflammatory diseases such as multiple sclerosis (MS) [8, 9]; stroke [10];…”
BackgroundMicroglial dysfunction in brain aging and Alzheimer's disease
Mosher, K. I., & Wyss-Coray, T. (2014) · Biochemical Pharmacology · doi:10.1016/j.bcp.2014.01.008 · Cited by 618
“But in point of fact, is has been argued that there has yet to be sufficient evidence that microglia are capable of true phagocytosis of Ab [149]; although microglia do appear to engulf amyloid, it is unclear whether the cells can degrade the protein.”
Background
Metadata
- Authors
- Prokop, S., Miller, K. R., & Heppner, F. L.
- Affiliations
- Charité – Universitätsmedizin Berlin (DE)
- Corresponding author
- Heppner, Frank L.
- Venue
- Acta Neuropathologica
- Published
- 2013-09-28
- Volume
- 126
- Issue
- 4
- Pages
- 461-477
- ISSN
- 0001-6322 (ISSN-L)
- 1432-0533
- OpenAlex
- W1995357368
- Cited by
- 291
- References
- 175
- Citations by year
- 2026: 4 · 2025: 15 · 2024: 15 · 2023: 19 · 2022: 15 · 2021: 19 · 2020: 29 · 2019: 27 · 2018: 31 · 2017: 36 · 2016: 23 · 2015: 28 · 2014: 29 · 2013: 1
- FWCI
- 2.62
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Acta Neuropathologica (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of Neurological Disorders and Stroke (R01NS046006)
- Topics
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Neurology › Neurological Disease Mechanisms and Treatments
- Keywords
- microglia, Alzheimer's disease, amyloid plaques, chronic neuroinflammation, microglial activation, microglial phagocytosis, neurodegeneration, microglial dysfunction, disease progression
- MeSH terms
- Alzheimer Disease, Animals, Humans, Macrophage Activation, Phenotype, Amyloid beta-Peptides, Cellular Senescence, Microglia, Myeloid Cells, Alzheimer Vaccines
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.